ANKRD12

Summary

ANKRD12 (ankyrin repeat domain 12, HGNC:29135) is a protein-coding gene on chromosome 18p11.22, encoding Ankyrin repeat domain-containing protein 12 (Q6UB98). May recruit HDACs to the p160 coactivators/nuclear receptor complex to inhibit ligand-dependent transactivation.

This gene encodes a member of the ankyrin repeats-containing cofactor family. These proteins may inhibit the transcriptional activity of nuclear receptors through the recruitment of histone deacetylases. The encoded protein interacts with p160 coactivators and also represses transcription mediated by the coactivator alteration/deficiency in activation 3 (ADA3). Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

Source: NCBI Gene 23253 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 290 total — 4 pathogenic
• MANE Select transcript: NM_015208

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29135
Approved symbol	ANKRD12
Name	ankyrin repeat domain 12
Location	18p11.22
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0874, FLJ20053, GAC-1, ANCO-2
Ensembl gene	ENSG00000101745
Ensembl biotype	protein_coding
OMIM	610616
Entrez	23253

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 10 protein_coding, 2 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined

ENST00000262126, ENST00000359158, ENST00000400020, ENST00000540578, ENST00000546007, ENST00000577992, ENST00000581635, ENST00000581758, ENST00000585234, ENST00000917028, ENST00000917029, ENST00000917030, ENST00000917031, ENST00000962123

RefSeq mRNA: 3 — MANE Select: NM_015208 NM_001083625, NM_001204056, NM_015208

CCDS: CCDS11843, CCDS42411

Canonical transcript exons

ENST00000262126 — 13 exons

Exon	Start	End
ENSE00000665940	9275524	9275667
ENSE00000665942	9279549	9279644
ENSE00001018057	9254211	9258931
ENSE00001018058	9263790	9263888
ENSE00001939942	9136781	9136965
ENSE00001949715	9280941	9285985
ENSE00003467074	9216758	9216900
ENSE00003504057	9182382	9182519
ENSE00003505486	9204476	9204544
ENSE00003585104	9221852	9221999
ENSE00003671931	9195551	9195698
ENSE00003673583	9208657	9208803
ENSE00003681082	9211584	9211784

Expression profiles

Bgee: expression breadth ubiquitous, 296 present calls, max score 98.59.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 40.6570 / max 4233.3839, expressed in 1799 samples.

FANTOM5 promoters (19 alternative TSS)

Promoter ID	TPM avg	Samples expressed
169334	26.1773	1776
169338	2.7570	747
169337	1.9882	798
169353	1.9861	487
169350	1.0713	287
169347	1.0564	355
169335	1.0092	322
169354	0.8581	239
169352	0.8483	225
169336	0.4950	211

Top tissues by expression

302 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	98.59	gold quality
sural nerve	UBERON:0015488	98.12	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	97.16	gold quality
colonic epithelium	UBERON:0000397	96.23	gold quality
tendon	UBERON:0000043	95.40	gold quality
cortical plate	UBERON:0005343	94.77	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	93.98	gold quality
endometrium epithelium	UBERON:0004811	93.43	gold quality
bone marrow cell	CL:0002092	92.78	gold quality
corpus callosum	UBERON:0002336	92.75	gold quality
epithelium of nasopharynx	UBERON:0001951	92.68	gold quality
nasopharynx	UBERON:0001728	92.67	gold quality
tonsil	UBERON:0002372	92.65	gold quality
monocyte	CL:0000576	92.55	gold quality
mononuclear cell	CL:0000842	92.41	gold quality
leukocyte	CL:0000738	91.72	gold quality
adrenal tissue	UBERON:0018303	91.40	gold quality
cerebellar vermis	UBERON:0004720	91.00	gold quality
superficial temporal artery	UBERON:0001614	90.65	gold quality
esophagus squamous epithelium	UBERON:0006920	89.56	gold quality
jejunal mucosa	UBERON:0000399	88.64	gold quality
bone marrow	UBERON:0002371	88.48	gold quality
vermiform appendix	UBERON:0001154	88.04	gold quality
ganglionic eminence	UBERON:0004023	88.03	gold quality
testis	UBERON:0000473	87.65	gold quality
lymph node	UBERON:0000029	87.61	gold quality
caecum	UBERON:0001153	87.48	gold quality
ventricular zone	UBERON:0003053	87.38	gold quality
skin of hip	UBERON:0001554	87.35	gold quality
cartilage tissue	UBERON:0002418	87.20	gold quality

Single-cell (SCXA)

Detected in 9 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-GEOD-124263	yes	956.41
E-CURD-122	yes	34.60
E-GEOD-93593	yes	18.56
E-MTAB-8142	yes	15.91
E-CURD-114	yes	10.93
E-MTAB-6379	no	2618.66
E-CURD-135	no	1630.31
E-MTAB-9543	no	2.37
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

217 targeting ANKRD12, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-32-5P	99.98	75.21	1964

Literature-anchored findings (GeneRIF, showing 3)

• ADA3 is a newly identified target of the ANCO proteins, which may modulate co-activator function in a transcription-factor-specific manner (PMID:18377363)
• Study revealed that ANKRD12 mRNA were down regulated in CRC tumor tissues and low ANKRD12 expression was correlated with liver metastasis and poor survival of CRC patients. (PMID:23718802)
• These results suggest that circANKRD12 could be involved in a diverse set of functions ranging from cell cycle arrest, tumor invasion to immune modulation. Manipulating the levels of circANKRD12 can regulate molecular functions by altering different signaling pathways and modifies the phenotype of the cells. (PMID:31185953)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ankrd12	ENSDARG00000052419
mus_musculus	Ankrd12	ENSMUSG00000034647
rattus_norvegicus	Ankrd12	ENSRNOG00000012733

Protein

Protein identifiers

Ankyrin repeat domain-containing protein 12 — Q6UB98 (reviewed: Q6UB98)

Alternative names: Ankyrin repeat-containing cofactor 2, GAC-1 protein

All UniProt accessions (6): Q6UB98, B5MEA4, F5GYX2, J3KS53, J3KSU9, J3QRX3

UniProt curated annotations — full annotation on UniProt →

Function. May recruit HDACs to the p160 coactivators/nuclear receptor complex to inhibit ligand-dependent transactivation.

Subunit / interactions. Interacts with the PAS region of the p160 coactivators.

Subcellular location. Nucleus.

Isoforms (2)

UniProt ID	Names	Canonical?
Q6UB98-1	1	yes
Q6UB98-2	2

RefSeq proteins (3): NP_001077094, NP_001190985, NP_056023* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002110	Ankyrin_rpt	Repeat
IPR036770	Ankyrin_rpt-contain_sf	Homologous_superfamily
IPR053210	ANKRD12	Family

Pfam: PF00023, PF12796

UniProt features (57 total): compositionally biased region 24, region of interest 12, sequence variant 10, modified residue 5, repeat 3, chain 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6UB98-F1	41.33	0.07

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 149, 543, 630, 861, 1401

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 240 (showing top): MORF_RAGE, AAGCAAT_MIR137, TGCACTT_MIR519C_MIR519B_MIR519A, MODULE_45, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, AAAYRNCTG_UNKNOWN, CAGCTG_AP4_Q5, SP1_Q2_01, ATGTTAA_MIR302C, DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN, USF_01, TGIF_01, MORF_PML, ATCATGA_MIR433, USF_02

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (3): nucleoplasm (GO:0005654), cytosol (GO:0005829), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
binding	1
nuclear lumen	1
cytoplasm	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1518 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ANKRD12	LRRC30	A6NM36	559
ANKRD12	PDE4DIP	Q5VU43	430
ANKRD12	ARHGAP28	Q9P2N2	423
ANKRD12	SLAIN2	Q9P270	404
ANKRD12	ZBTB14	O43829	402
ANKRD12	CDKN2A	P42771	395
ANKRD12	NDUFV2	P19404	388
ANKRD12	WIZ	O95785	380
ANKRD12	AKAIN1	P0CW23	370
ANKRD12	MTCL1	Q9Y4B5	358
ANKRD12	BRCA1	P38398	348
ANKRD12	WDSUB1	Q8N9V3	331
ANKRD12	SAMD10	Q9BYL1	330
ANKRD12	ZNF579	Q8NAF0	324
ANKRD12	SLAIN1	Q8ND83	323

IntAct

22 interactions, top by confidence:

A	B	Type	Score
GPS2	HDAC3	psi-mi:“MI:0914”(association)	0.900
HDAC3	KDM1A	psi-mi:“MI:0914”(association)	0.650
GPS2	DCTN6	psi-mi:“MI:0914”(association)	0.530
FOXM1	ANKRD12	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
ANKRD12	CDK6	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
CDK4	ANKRD12	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
ANKRD12	TMTC3	psi-mi:“MI:0915”(physical association)	0.400
ANKRD12	HNRNPD	psi-mi:“MI:0915”(physical association)	0.400
	ANKRD12	psi-mi:“MI:0915”(physical association)	0.370
COPS5	FBLL1	psi-mi:“MI:0914”(association)	0.350
P		psi-mi:“MI:0914”(association)	0.350
ANKRD12	SLIT2	psi-mi:“MI:0914”(association)	0.350
ANKRD12	SGPL1	psi-mi:“MI:0914”(association)	0.350
MTNR1A	ANKRD12	psi-mi:“MI:0915”(physical association)	0.000
DISC1	ANKRD12	psi-mi:“MI:0915”(physical association)	0.000
ANKRD12	EEF1D	psi-mi:“MI:0915”(physical association)	0.000
	ANKRD12	psi-mi:“MI:0915”(physical association)	0.000
ANKRD12	lepA	psi-mi:“MI:0915”(physical association)	0.000
ANKRD12	pxpA	psi-mi:“MI:0915”(physical association)	0.000
ANKRD12	yopM	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (50): SGPL1 (Affinity Capture-MS), GLIPR2 (Affinity Capture-MS), PHYHIP (Affinity Capture-MS), FYN (Affinity Capture-MS), YES1 (Affinity Capture-MS), ULBP2 (Affinity Capture-MS), SLIT2 (Affinity Capture-MS), HIF1AN (Affinity Capture-MS), GNB4 (Affinity Capture-MS), SGPL1 (Affinity Capture-MS), PHYHIP (Affinity Capture-MS), ULBP2 (Affinity Capture-MS), SLIT2 (Affinity Capture-MS), ANKRD12 (Two-hybrid), ANKRD12 (Affinity Capture-RNA)

ESM2 similar proteins: A0A1I8MUL8, A2AG58, A2AJT9, E9Q309, E9Q4F7, F4JC20, F4KDH9, O23372, O35698, O94687, P0DW16, P78332, Q01613, Q14966, Q17QQ9, Q27IV2, Q2T9M9, Q32KY7, Q32PP1, Q3UQS8, Q4R731, Q53FD0, Q5LJZ2, Q5PPL1, Q5R6I3, Q5T481, Q5VT06, Q60990, Q61464, Q6AYU0, Q6H7U2, Q6IMN6, Q6P9P0, Q6UB98, Q6UB99, Q86V48, Q8BYK8, Q8CH25, Q8IH18, Q8K2H1

Diamond homologs: E9Q4F7, Q6UB98, Q6UB99

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

290 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	4
Likely pathogenic	0
Uncertain significance	252
Likely benign	16
Benign	1

Top pathogenic / likely-pathogenic (4)

Variant ID	HGVS	Classification
1526591	GRCh37/hg19 18p11.32-11.21(chr18:136226-13655146)	Pathogenic
33085	GRCh38/hg38 18p11.32-q23(chr18:148963-80252149)x3	Pathogenic
58752	GRCh38/hg38 18p11.23-11.22(chr18:7542605-9320894)x3	Pathogenic
59957	GRCh38/hg38 18p11.31-11.22(chr18:7154668-10068356)x1	Pathogenic

SpliceAI

2828 predictions. Top by Δscore:

Variant	Effect	Δscore
18:9182516:AAAG:A	donor_loss	1.0000
18:9182517:AAGG:A	donor_loss	1.0000
18:9182518:AGG:A	donor_loss	1.0000
18:9182519:GG:G	donor_loss	1.0000
18:9182520:GTAT:G	donor_loss	1.0000
18:9182521:T:G	donor_loss	1.0000
18:9195546:A:AG	acceptor_gain	1.0000
18:9195548:T:G	acceptor_gain	1.0000
18:9195549:A:AG	acceptor_gain	1.0000
18:9195550:G:C	acceptor_gain	1.0000
18:9195550:G:GG	acceptor_gain	1.0000
18:9195550:GA:G	acceptor_gain	1.0000
18:9195550:GAG:G	acceptor_loss	1.0000
18:9195550:GAGT:G	acceptor_gain	1.0000
18:9195550:GAGTA:G	acceptor_gain	1.0000
18:9208799:TCCAG:T	donor_loss	1.0000
18:9208800:CCAGG:C	donor_loss	1.0000
18:9208801:CAG:C	donor_loss	1.0000
18:9208802:AGG:A	donor_loss	1.0000
18:9208803:GGTGA:G	donor_loss	1.0000
18:9208804:G:A	donor_loss	1.0000
18:9208825:T:G	donor_gain	1.0000
18:9211579:TACA:T	acceptor_loss	1.0000
18:9211580:ACAG:A	acceptor_loss	1.0000
18:9211581:CA:C	acceptor_loss	1.0000
18:9211582:A:AC	acceptor_loss	1.0000
18:9211582:A:AG	acceptor_gain	1.0000
18:9211583:G:GA	acceptor_gain	1.0000
18:9211583:GA:G	acceptor_gain	1.0000
18:9211583:GAT:G	acceptor_gain	1.0000

AlphaMissense

13797 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
18:9211698:T:C	L189S	1.000
18:9211710:C:A	A193D	1.000
18:9211719:G:T	G196V	1.000
18:9211775:G:C	D215H	1.000
18:9211776:A:C	D215A	1.000
18:9211776:A:G	D215G	1.000
18:9211776:A:T	D215V	1.000
18:9211777:T:A	D215E	1.000
18:9211777:T:G	D215E	1.000
18:9216760:T:A	W219R	1.000
18:9216760:T:C	W219R	1.000
18:9216761:G:C	W219S	1.000
18:9216762:G:C	W219C	1.000
18:9216762:G:T	W219C	1.000
18:9216767:C:A	P221Q	1.000
18:9216767:C:G	P221R	1.000
18:9216770:T:A	L222Q	1.000
18:9216770:T:C	L222P	1.000
18:9216772:C:G	H223D	1.000
18:9216773:A:C	H223P	1.000
18:9216773:A:G	H223R	1.000
18:9216778:G:C	A225P	1.000
18:9216781:T:C	C226R	1.000
18:9216782:G:A	C226Y	1.000
18:9216783:C:G	C226W	1.000
18:9216791:G:A	G229E	1.000
18:9216791:G:T	G229V	1.000
18:9216806:C:A	A234D	1.000
18:9216815:T:A	L237H	1.000
18:9216815:T:C	L237P	1.000

dbSNP variants (sampled 300 via entrez): RS1000015089 (18:9165823 C>G,T), RS1000026401 (18:9251185 C>G,T), RS1000046153 (18:9168018 A>G), RS1000047148 (18:9173094 G>A,T), RS1000092925 (18:9249960 G>C), RS1000117114 (18:9272519 A>G), RS1000127927 (18:9136181 G>A), RS1000169617 (18:9170579 C>G), RS1000195279 (18:9144616 A>G), RS1000227548 (18:9207572 C>A,G), RS1000248654 (18:9267250 T>A), RS1000249627 (18:9214179 T>G), RS1000279458 (18:9180836 T>A), RS1000302590 (18:9239410 G>C), RS1000310048 (18:9252315 C>T)

Disease associations

OMIM: gene MIM:610616 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST002945_17	Emphysema imaging phenotypes	4.000000e-07
GCST002945_38	Emphysema imaging phenotypes	4.000000e-07
GCST90002390_548	Mean corpuscular hemoglobin	1.000000e-10
GCST90002392_28	Mean corpuscular volume	1.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007626	emphysema imaging measurement
EFO:0004527	mean corpuscular hemoglobin

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

64 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, decreases methylation	5
trichostatin A	affects cotreatment, decreases expression, affects expression	3
bisphenol A	decreases expression, affects cotreatment, increases methylation	2
Tetrachlorodibenzodioxin	increases expression	2
Cyclosporine	increases expression, increases methylation	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
bisphenol F	affects cotreatment, decreases expression	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
arsenite	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	increases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	increases response to substance, increases expression	1
bisphenol S	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
NSC 689534	affects binding, increases expression	1
PCI 5002	affects cotreatment, increases expression	1
3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol	decreases expression	1
Arsenic Trioxide	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Leflunomide	increases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer